nach oben

Erschienen in:

12.05.2017 | Research Agenda

The intensive care medicine research agenda on septic shock

verfasst von: Anders Perner, Anthony C. Gordon, Derek C. Angus, Francois Lamontagne, Flavia Machado, James A. Russell, Jean-Francois Timsit, John C. Marshall, John Myburgh, Manu Shankar-Hari, Mervyn Singer

Erschienen in: Intensive Care Medicine | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

Septic shock remains a global health challenge with millions of cases every year, high rates of mortality and morbidity, impaired quality of life among survivors and relatives, and high resource use both in developed and developing nations. Care and outcomes are improving through organisational initiatives and updated clinical practice guidelines based on clinical research mainly carried out by large collaborative networks. This progress is likely to continue through the collaborative work of the established and merging trials groups in many parts of the world and through refined trial methodology and translational work. In this review, international experts summarize the current position of clinical research in septic shock and propose a research agenda to advance this field.

Bernard GR, Vincent JL, Laterre PF et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709. doi:10.1056/NEJM200103083441001 PubMedCrossRef

Ranieri VM, Thompson BT, Barie PS et al (2012) Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366:2055–2064. doi:10.1056/NEJMoa1202290 PubMedCrossRef

Angus DC (2011) The search for effective therapy for sepsis: back to the drawing board? JAMA 306:2614–2615. doi:10.1001/jama.2011.1853 PubMedCrossRef

Singer M, Deutschman CS, Seymour CW et al (2016) The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315:801–810. doi:10.1001/jama.2016.0287 PubMedPubMedCentralCrossRef

Rhodes A, Evans LE, Alhazzani W et al (2017) Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. doi:10.1007/s00134-017-4683-6

Levy MM, Rhodes A, Phillips GS et al (2014) Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study. Intensive Care Med 40:1623–1633. doi:10.1007/s00134-014-3496-0 PubMedCrossRef

Aaronson EL, Filbin MR, Brown DFM et al (2016) New mandated centers for medicare and medicaid services requirements for sepsis reporting: caution from the field. J Emerg Med. doi:10.1016/j.jemermed.2016.08.009

Phua J, Koh Y, Du B et al (2011) Management of severe sepsis in patients admitted to Asian intensive care units: prospective cohort study. BMJ 342:d3245PubMedPubMedCentralCrossRef

Noritomi DT, Ranzani OT, Monteiro MB et al (2014) Implementation of a multifaceted sepsis education program in an emerging country setting: clinical outcomes and cost-effectiveness in a long-term follow-up study. Intensive Care Med 40:182–191. doi:10.1007/s00134-013-3131-5 PubMedCrossRef

10.

Rhodes A, Phillips G, Beale R et al (2015) The Surviving Sepsis Campaign bundles and outcome: results from the International Multicentre Prevalence Study on Sepsis (the IMPreSS study). Intensive Care Med 41:1620–1628. doi:10.1007/s00134-015-3906-y PubMedCrossRef

11.

Shin TG, Jo IJ, Choi DJ et al (2013) The adverse effect of emergency department crowding on compliance with the resuscitation bundle in the management of severe sepsis and septic shock. Crit Care Lond Engl 17:R224. doi:10.1186/cc13047 CrossRef

12.

Almeida M, Ribeiro O, Aragão I et al (2013) Differences in compliance with Surviving Sepsis Campaign recommendations according to hospital entrance time: day versus night. Crit Care Lond Engl 17:R79. doi:10.1186/cc12689 CrossRef

13.

Borgert MJ, Goossens A, Dongelmans DA (2015) What are effective strategies for the implementation of care bundles on ICUs: a systematic review. Implement Sci IS 10:119. doi:10.1186/s13012-015-0306-1 PubMedCrossRef

14.

Pocock SJ, Stone GW (2016) The primary outcome is positive—is that good enough? N Engl J Med 375:971–979. doi:10.1056/NEJMra1601511 PubMedCrossRef

15.

Pocock SJ, Stone GW (2016) The primary outcome fails—what next? N Engl J Med 375:861–870. doi:10.1056/NEJMra1510064 PubMedCrossRef

16.

Harhay MO, Wagner J, Ratcliffe SJ et al (2014) Outcomes and statistical power in adult critical care randomized trials. Am J Respir Crit Care Med 189:1469–1478. doi:10.1164/rccm.201401-0056CP PubMedPubMedCentralCrossRef

17.

Zarychanski R, Abou-Setta AM, Turgeon AF et al (2013) Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 309:678–688. doi:10.1001/jama.2013.430 PubMedCrossRef

18.

Iwashyna TJ, Burke JF, Sussman JB et al (2015) Implications of heterogeneity of treatment effect for reporting and analysis of randomized trials in critical care. Am J Respir Crit Care Med 192:1045–1051. doi:10.1164/rccm.201411-2125CP PubMedPubMedCentralCrossRef

19.

Rivers E, Nguyen B, Havstad S et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377. doi:10.1056/NEJMoa010307 PubMedCrossRef

20.

Investigators ProCESS, Yealy DM, Kellum JA et al (2014) A randomized trial of protocol-based care for early septic shock. N Engl J Med 370:1683–1693. doi:10.1056/NEJMoa1401602 CrossRef

21.

Peake SL, ARISE Investigators, ANZICS Clinical Trials Group et al (2014) Goal-directed resuscitation for patients with early septic shock. N Engl J Med 371:1496–1506. doi:10.1056/NEJMoa1404380 PubMedCrossRef

22.

Mouncey PR, Osborn TM, Power GS et al (2015) Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 372:1301–1311. doi:10.1056/NEJMoa1500896 PubMedCrossRef

23.

ProCESS ARISE, Committee ProMISe Methodology Writing, Huang DT, Angus DC et al (2013) Harmonizing international trials of early goal-directed resuscitation for severe sepsis and septic shock: methodology of ProCESS, ARISE, and ProMISe. Intensive Care Med 39:1760–1775. doi:10.1007/s00134-013-3024-7 CrossRef

24.

PRISM Investigators (2017) Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis. N Engl J Med. doi:10.1056/NEJMoa1701380

25.

Maitland K, Kiguli S, Opoka RO et al (2011) Mortality after fluid bolus in African children with severe infection. N Engl J Med 364:2483–2495. doi:10.1056/NEJMoa1101549 PubMedCrossRef

26.

Hjortrup PB, Haase N, Bundgaard H et al (2016) Restricting volumes of resuscitation fluid in adults with septic shock after initial management: the CLASSIC randomised, parallel-group, multicentre feasibility trial. Intensive Care Med 42:1695–1705. doi:10.1007/s00134-016-4500-7 PubMedCrossRef

27.

Girardis M, Busani S, Damiani E et al (2016) Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. JAMA 316:1583–1589. doi:10.1001/jama.2016.11993 PubMedCrossRef

28.

Angus DC, Linde-Zwirble WT, Lidicker J et al (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303–1310PubMedCrossRef

29.

Perner A, Haase N, Winkel P et al (2014) Long-term outcomes in patients with severe sepsis randomised to resuscitation with hydroxyethyl starch 130/0.42 or Ringer’s acetate. Intensive Care Med 40:927–934. doi:10.1007/s00134-014-3311-y PubMedCrossRef

30.

Mayr FB, Talisa VB, Balakumar V et al (2017) Proportion and cost of unplanned 30-day readmissions after sepsis compared with other medical conditions. JAMA 317:530–531. doi:10.1001/jama.2016.20468 PubMedCrossRef

31.

Herridge MS, Chu LM, Matte A et al (2016) The RECOVER Program: disability risk groups and 1-year outcome after 7 or more days of mechanical ventilation. Am J Respir Crit Care Med 194:831–844. doi:10.1164/rccm.201512-2343OC PubMedCrossRef

32.

Cameron JI, Wittenberg E, Prosser LA (2016) Caregivers and families of critically Ill patients. N Engl J Med 375:1000–1002. doi:10.1056/NEJMc1608225 PubMedCrossRef

33.

Lamontagne F, Cohen D, Herridge M (2016) Understanding patient-centredness: contrasting expert versus patient perspectives on vasopressor therapy for shock. Intensive Care Med. doi:10.1007/s00134-016-4518-x

34.

Selby JV, Forsythe L, Sox HC (2015) Stakeholder-driven comparative effectiveness research: an update from PCORI. JAMA 314:2235–2236. doi:10.1001/jama.2015.15139 PubMedCrossRef

35.

Bafeta A, Dechartres A, Trinquart L et al (2012) Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study. BMJ 344:e813PubMedPubMedCentralCrossRef

36.

Wiedermann CJ, Bellomo R, Perner A (2016) Is the literature inconclusive about the harm from HES? No. Intensive Care Med. doi:10.1007/s00134-016-4275-x PubMed

37.

Landoni G, Comis M, Conte M et al (2015) Mortality in multicenter critical care trials: an analysis of interventions with a significant effect. Crit Care Med 43:1559–1568. doi:10.1097/CCM.0000000000000974 PubMedCrossRef

38.

Angus DC, Barnato AE, Bell D et al (2015) A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, ProCESS and ProMISe Investigators. Intensive Care Med 41:1549–1560. doi:10.1007/s00134-015-3822-1 PubMedCrossRef

39.

Ranieri VM, Thompson BT, Finfer S et al (2011) Unblinding plan of PROWESS-SHOCK trial. Intensive Care Med 37:1384–1385. doi:10.1007/s00134-011-2272-7 PubMedCrossRef

40.

Perner A, Haase N, Guttormsen AB et al (2012) Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 367:124–134. doi:10.1056/NEJMoa1204242 PubMedCrossRef

41.

Myburgh JA, Finfer S, Bellomo R et al (2012) Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 367:1901–1911. doi:10.1056/NEJMoa1209759 PubMedCrossRef

42.

Haase N, Wetterslev J, Winkel P, Perner A (2013) Bleeding and risk of death with hydroxyethyl starch in severe sepsis: post hoc analyses of a randomized clinical trial. Intensive Care Med 39:2126–2134. doi:10.1007/s00134-013-3111-9 PubMedCrossRef

43.

Bion J, Bellomo R, Myburgh J et al (2014) Hydroxyethyl starch: putting patient safety first. Intensive Care Med 40:256–259. doi:10.1007/s00134-013-3167-6 PubMedCrossRef

44.

Hébert PC, Wells G, Blajchman MA et al (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 340:409–417. doi:10.1056/NEJM199902113400601 PubMedCrossRef

45.

Holst LB, Haase N, Wetterslev J et al (2014) Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 371:1381–1391. doi:10.1056/NEJMoa1406617 PubMedCrossRef

46.

Rygård SL, Holst LB, Wetterslev J et al (2016) Long-term outcomes in patients with septic shock transfused at a lower versus a higher haemoglobin threshold: the TRISS randomised, multicentre clinical trial. Intensive Care Med 42:1685–1694. doi:10.1007/s00134-016-4437-x PubMedCrossRef

47.

Lundh A, Sismondo S, Lexchin J, et al (2012) Industry sponsorship and research outcome. Cochrane Database Syst Rev 12: MR000033. doi: 10.1002/14651858.MR000033.pub2

48.

Savović J, Jones HE, Altman DG et al (2012) Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 157:429–438. doi:10.7326/0003-4819-157-6-201209180-00537 PubMedCrossRef

49.

Ziff OJ, Lane DA, Samra M et al (2015) Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 351:h4451PubMedPubMedCentralCrossRef

50.

Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228. doi:10.1007/s00134-012-2769-8 PubMedCrossRef

51.

Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924–926. doi:10.1136/bmj.39489.470347.AD PubMedPubMedCentralCrossRef

52.

Shankar-Hari M, Phillips GS, Levy ML et al (2016) Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315:775–787. doi:10.1001/jama.2016.0289 PubMedPubMedCentralCrossRef

53.

Sterling SA, Miller WR, Pryor J et al (2015) The impact of timing of antibiotics on outcomes in severe sepsis and septic shock: a systematic review and meta-analysis. Crit Care Med 43:1907–1915. doi:10.1097/CCM.0000000000001142 PubMedPubMedCentralCrossRef

54.

de Groot B, Ansems A, Gerling DH et al (2015) The association between time to antibiotics and relevant clinical outcomes in emergency department patients with various stages of sepsis: a prospective multi-center study. Crit Care Lond Engl 19:194. doi:10.1186/s13054-015-0936-3 CrossRef

55.

McGregor JC, Rich SE, Harris AD et al (2007) A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis 45:329–337. doi:10.1086/519283 PubMedCrossRef

56.

Eyler RF, Mueller BA, Medscape (2011) Antibiotic dosing in critically ill patients with acute kidney injury. Nat Rev Nephrol 7:226–235. doi:10.1038/nrneph.2011.12 PubMedCrossRef

57.

Abdul-Aziz MH, Sulaiman H, Mat-Nor M-B et al (2016) Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med 42:1535–1545. doi:10.1007/s00134-015-4188-0 PubMedCrossRef

58.

Roberts JA, Taccone FS, Lipman J (2016) Understanding PK/PD. Intensive Care Med 42:1797–1800. doi:10.1007/s00134-015-4032-6 PubMedCrossRef

59.

Shankar-Hari M, Harrison DA, Rowan KM (2016) Differences in impact of definitional elements on mortality precludes international comparisons of sepsis epidemiology-A cohort study illustrating the need for standardized reporting. Crit Care Med 44:2223–2230. doi:10.1097/CCM.0000000000001876 PubMedCrossRef

60.

Kaukonen K-M, Bailey M, Suzuki S et al (2014) Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 311:1308–1316. doi:10.1001/jama.2014.2637 PubMedCrossRef

61.

Spellberg B, Bartlett JG, Gilbert DN (2013) The future of antibiotics and resistance. N Engl J Med 368:299–302. doi:10.1056/NEJMp1215093 PubMedPubMedCentralCrossRef

62.

Perner A, Gordon AC, De Backer D et al (2016) Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy. Intensive Care Med 42:1958–1969. doi:10.1007/s00134-016-4577-z PubMedCrossRef

63.

Asfar P, Meziani F, Hamel J-F et al (2014) High versus low blood-pressure target in patients with septic shock. N Engl J Med 370:1583–1593. doi:10.1056/NEJMoa1312173 PubMedCrossRef

64.

Rygård SL, Holst LB, Wetterslev J et al (2017) Higher vs. lower haemoglobin threshold for transfusion in septic shock: subgroup analyses of the TRISS trial. Acta Anaesthesiol Scand 61:166–175. doi:10.1111/aas.12837 PubMedCrossRef

65.

Russell JA, Lee T, Singer J et al (2017) The septic shock 3.0 definition and trials: a vasopressin and septic shock trial experience. Crit Care. doi:10.1097/CCM.0000000000002323

66.

Seymour CW, Liu VX, Iwashyna TJ et al (2016) Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315:762–774. doi:10.1001/jama.2016.0288 PubMedPubMedCentralCrossRef

67.

Bhattacharjee P, Edelson DP, Churpek MM (2016) Identifying patients with sepsis on the hospital wards. Chest. doi:10.1016/j.chest.2016.06.020 PubMedCentral

68.

Cohen J, Vincent J-L, Adhikari NKJ et al (2015) Sepsis: a roadmap for future research. Lancet Infect Dis 15:581–614. doi:10.1016/S1473-3099(15)70112-X PubMedCrossRef

69.

Prescott HC, Calfee CS, Thompson BT et al (2016) Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design. Am J Respir Crit Care Med 194:147–155. doi:10.1164/rccm.201512-2544CP PubMedPubMedCentralCrossRef

70.

Famous KR, Delucchi K, Ware LB et al (2016) ARDS subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med. doi:10.1164/rccm.201603-0645OC

71.

Wong HR, Cvijanovich NZ, Anas N et al (2015) Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med 191:309–315. doi:10.1164/rccm.201410-1864OC PubMedPubMedCentralCrossRef

72.

Hotchkiss RS, Sherwood ER (2015) Immunology. Getting sepsis therapy right. Science 347:1201–1202. doi:10.1126/science.aaa8334 PubMedPubMedCentralCrossRef

73.

Iwashyna TJ, Liu V (2014) What’s so different about big data?. A primer for clinicians trained to think epidemiologically. Ann Am Thorac Soc 11:1130–1135. doi:10.1513/AnnalsATS.201405-185AS PubMedPubMedCentralCrossRef

74.

Heyland DK, Muscedere J, Drover J et al (2011) Persistent organ dysfunction plus death: a novel, composite outcome measure for critical care trials. Crit Care Lond Engl 15:R98. doi:10.1186/cc10110 CrossRef

75.

Montori VM, Permanyer-Miralda G, Ferreira-González I et al (2005) Validity of composite end points in clinical trials. BMJ 330:594–596. doi:10.1136/bmj.330.7491.594 PubMedPubMedCentralCrossRef

76.

Boyd JH, Forbes J, Nakada T et al (2011) Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 39:259–265. doi:10.1097/CCM.0b013e3181feeb15 PubMedCrossRef

77.

Wiedemann HP, Wheeler AP, National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network et al (2006) Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 354:2564–2575. doi:10.1056/NEJMoa062200 PubMedCrossRef

78.

Hranjec T, Rosenberger LH, Swenson B et al (2012) Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: a quasi-experimental, before and after observational cohort study. Lancet Infect Dis 12:774–780. doi:10.1016/S1473-3099(12)70151-2 PubMedPubMedCentralCrossRef

79.

Lamontagne F, Meade MO, Hébert PC et al (2016) Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot randomized controlled trial. Intensive Care Med 42:542–550. doi:10.1007/s00134-016-4237-3 PubMedCrossRef

80.

Russell JA, Walley KR, Singer J et al (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358:877–887. doi:10.1056/NEJMoa067373 PubMedCrossRef

81.

Gordon AC, Mason AJ, Thirunavukkarasu N et al (2016) Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 316:509–518. doi:10.1001/jama.2016.10485 PubMedCrossRef

82.

Chawla LS, Busse L, Brasha-Mitchell E et al (2014) Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care Lond Engl 18:534. doi:10.1186/s13054-014-0534-9 CrossRef

83.

Morelli A, Ertmer C, Westphal M et al (2013) Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 310:1683–1691. doi:10.1001/jama.2013.278477 PubMedCrossRef

84.

Dishy V, Sofowora GG, Xie HG et al (2001) The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 345:1030–1035. doi:10.1056/NEJMoa010819 PubMedCrossRef

85.

Laukkanen JA, Mäkikallio TH, Kauhanen J, Kurl S (2009) Insertion/deletion polymorphism in alpha2-adrenergic receptor gene is a genetic risk factor for sudden cardiac death. Am Heart J 158:615–621. doi:10.1016/j.ahj.2009.07.023 PubMedCrossRef

86.

Nakada T-A, Russell JA, Boyd JH et al (2010) beta2-Adrenergic receptor gene polymorphism is associated with mortality in septic shock. Am J Respir Crit Care Med 181:143–149. doi:10.1164/rccm.200903-0332OC PubMedCrossRef

87.

Venkatesh B, Myburgh J, Finfer S et al (2013) The ADRENAL study protocol: adjunctive corticosteroid treatment in critically ill patients with septic shock. Crit Care Resusc 15:83–88PubMed

88.

Bentzer P, Fjell C, Walley KR et al (2016) Plasma cytokine levels predict response to corticosteroids in septic shock. Intensive Care Med 42:1970–1979. doi:10.1007/s00134-016-4338-z PubMedCrossRef

89.

Marik PE, Khangoora V, Rivera R et al (2016) Hydrocortisone, Vitamin C and Thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study. Chest. doi:10.1016/j.chest.2016.11.036 PubMed

90.

Brealey D, Brand M, Hargreaves I et al (2002) Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 360:219–223. doi:10.1016/S0140-6736(02)09459-X PubMedCrossRef

91.

Lowes DA, Webster NR, Murphy MP, Galley HF (2013) Antioxidants that protect mitochondria reduce interleukin-6 and oxidative stress, improve mitochondrial function, and reduce biochemical markers of organ dysfunction in a rat model of acute sepsis. Br J Anaesth 110:472–480. doi:10.1093/bja/aes577 PubMedPubMedCentralCrossRef

92.

Lancel S, Hassoun SM, Favory R et al (2009) Carbon monoxide rescues mice from lethal sepsis by supporting mitochondrial energetic metabolism and activating mitochondrial biogenesis. J Pharmacol Exp Ther 329:641–648. doi:10.1124/jpet.108.148049 PubMedCrossRef

93.

Walter J, Ware LB, Matthay MA (2014) Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. Lancet Respir Med 2:1016–1026. doi:10.1016/S2213-2600(14)70217-6 PubMedCrossRef

94.

Fisher CJ, Agosti JM, Opal SM et al (1996) Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334:1697–1702. doi:10.1056/NEJM199606273342603 PubMedCrossRef

95.

Reinhart K, Menges T, Gardlund B et al (2001) Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: the RAMSES Study. Crit Care Med 29:765–769PubMedCrossRef

96.

Walley KR, Thain KR, Russell JA et al (2014) PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med 6:258ra143. doi:10.1126/scitranslmed.3008782 PubMedPubMedCentralCrossRef

97.

Davenport EE, Burnham KL, Radhakrishnan J et al (2016) Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med 4:259–271. doi:10.1016/S2213-2600(16)00046-1 PubMedPubMedCentralCrossRef

98.

Hotchkiss RS, Monneret G, Payen D (2013) Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 13:260–268. doi:10.1016/S1473-3099(13)70001-X PubMedPubMedCentralCrossRef

99.

Tsoukalas A, Albertson T, Tagkopoulos I (2015) From data to optimal decision making: a data-driven, probabilistic machine learning approach to decision support for patients with sepsis. JMIR Med Inform 3:e11. doi:10.2196/medinform.3445 PubMedPubMedCentralCrossRef

100.

James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163–1177. doi:10.1016/S0140-6736(15)01037-5 PubMedPubMedCentralCrossRef

101.

Angus DC (2015) Fusing randomized trials with big data: the key to self-learning health care systems? JAMA 314:767–768. doi:10.1001/jama.2015.7762 PubMedCrossRef

102.

Shankar-Hari M, Rubenfeld GD (2017) The use of enrichment to reduce statistically indeterminate or negative trials in critical care. Anaesthesia 72:560–565. doi:10.1111/anae.13870 PubMedCrossRef

Titel: The intensive care medicine research agenda on septic shock
verfasst von: Anders Perner
Anthony C. Gordon
Derek C. Angus
Francois Lamontagne
Flavia Machado
James A. Russell
Jean-Francois Timsit
John C. Marshall
John Myburgh
Manu Shankar-Hari
Mervyn Singer
Publikationsdatum: 12.05.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Intensive Care Medicine / Ausgabe 9/2017
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-017-4821-1

Neu im Fachgebiet AINS

23.04.2024 | Appendizitis | Nachrichten

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

The intensive care medicine research agenda on septic shock

Abstract

Neu im Fachgebiet AINS

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

S3-Leitlinie zu Pankreaskrebs aktualisiert

Update AINS

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2017

Current research priorities in perioperative intensive care medicine

The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship

Mortality rate is higher in Polish intensive care units than in other European countries

Pulmonary embolism following severe traumatic brain injury: incidence, risk factors and impact outcome

The status of intensive care medicine research and a future agenda for very old patients in the ICU

Trichosporon inkin disseminated infection

Neu im Fachgebiet AINS

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

S3-Leitlinie zu Pankreaskrebs aktualisiert

Update AINS